Investment Rating - The report highlights a positive outlook for the infant and child industry, particularly in light of recent government policies aimed at boosting birth rates and consumer spending in this sector [2][4]. Core Insights - The introduction of substantial child-rearing subsidies in cities like Hohhot is expected to accelerate the deployment of national-level child-rearing policies, positively impacting the infant and child market [2][5]. - The Chinese maternal and infant market is projected to grow from approximately 5.1 trillion yuan in 2023 to 5.4 trillion yuan in 2024, driven by increased consumer spending despite a declining birth rate [6]. - Companies like Kidswant are implementing aggressive expansion strategies to capture market share, particularly in lower-tier cities, which will likely enhance their market penetration [7]. Summary by Sections Policy Impact - Hohhot's child-rearing subsidy of 12,000 yuan for the first child and 30,000 yuan for the second child is significantly higher than previous city-level policies, indicating a potential shift in national policy [2]. - Following similar policies in Tianmen, the birth rate increased by 17% in 2024, demonstrating the effectiveness of financial incentives in boosting birth rates in lower-tier cities [4]. Market Size and Growth - The average annual spending on children in Chinese families ranges from 17,000 to 25,000 yuan, suggesting that the new subsidies could significantly increase consumer spending in the infant and child sector [2][3]. - The infant and child product market, particularly for ages 0-6, is estimated to be around 500 billion yuan, with essential goods like milk powder and diapers making up a substantial portion [6]. Company Strategies - Kidswant's "Three Expansion" strategy aims to open franchise stores in 1,000 counties by 2025, alongside investments in e-commerce and AI technologies to enhance customer engagement [7]. - Goodbaby International, a key player in the durable infant products market, is expected to benefit from the favorable policies due to its established brand and comprehensive product range [10]. Consumer Trends - Despite a decline in the population of children aged 0-14, spending on children's clothing and shoes has increased, indicating a shift in consumer priorities towards quality and functionality [12]. - The children's apparel market is projected to grow, with brands like Balabala maintaining a significant market share despite competitive pressures [13]. Future Outlook - The report suggests that the infant and child market will see a recovery in demand, particularly in the 0-6 age segment, driven by favorable government policies and increased consumer spending [14]. - Companies with strong market positions and innovative strategies, such as Goodbaby International and Kidswant, are well-positioned to capitalize on these trends [14].

今日早参 2025 年 3 月 11 日 仇文竹 债券策略研究组长 座机：13910895671 邮箱：qiuwenzhu@htsc.com 今日热点 宏观：2 月 PMI：全球总体扩张，但美国不无隐忧 本系列为华泰宏观出品、全球 PMI 月度追踪系列的第二十期。2 月全球制造 业 PMI 连续 2 个月位于荣枯线上方，显示制造业需求仍在修复：新订单、新 出口、价格分项均回升；关税导致的抢出口或推高制造业 PMI。全球服务业 PMI 延续高位回落，其中，美国回落幅度较大，经济前景存在一定隐忧，南 欧、日本高位扩张；新兴市场经济体除印度、巴西外多数回落。 风险提示：全球贸易需求超预期走弱，地缘政治冲突升级。 研报发布日期：2025-03-10 研究员 易峘 SAC:S0570520100005 SFC:AMH263 胡李鹏 SAC:S0570525010001 陈玮 SAC:S0570524030003 SFC:BVH374 固定收益：24Q4 ABS 投资者行为面面观 公募基金持仓市值已连续 12 个季度下降，企业应收账款类、供应链应付账款 类基础资产与中短期限、高评级标的仍为投资者重点偏好，但企业应收账款 ...

Core Viewpoint - The "pure pharmaceutical" funds have achieved the best performance among public QDII funds, highlighting a significant shift in investment focus away from popular AI and technology sectors towards undervalued pharmaceutical stocks [1][2][3] Group 1: Performance of Pharmaceutical Funds - As of March 5, the Huatai-PineBridge Hong Kong Advantage Select Fund achieved a year-to-date return of 23%, ranking first among Hong Kong and QDII funds, with a significant portion of its assets (89%) allocated to pharmaceutical stocks [2][3] - Other funds, such as the Jiashi Mutual Fund and Ping An Core Advantage Fund, also reported strong performances with returns of 22% and 20% respectively, focusing entirely on pharmaceutical stocks without exposure to AI or internet healthcare [4][5] Group 2: Market Dynamics and Trends - The shift towards pharmaceutical stocks by fund managers indicates a strong confidence in the recovery of this sector, despite the popularity of AI and technology stocks [4][6] - Non-pharmaceutical funds have begun to reallocate their portfolios towards pharmaceutical stocks, reflecting a trend of recognizing the potential for growth in this sector [6][12] Group 3: Technological Breakthroughs and Global Market Impact - Chinese pharmaceutical companies are experiencing significant breakthroughs, as evidenced by the collaboration between Kangfang Bio and Summit Therapeutics, which has led to a dramatic increase in stock prices [8][9][10] - The share of Chinese pharmaceutical companies in global drug transactions has increased from less than 5% in 2020 to over 20% in 2024, indicating a growing influence in the global pharmaceutical market [9][10] Group 4: Future Outlook for the Pharmaceutical Sector - The introduction of new drugs into the medical insurance system, with a majority being newly listed products, suggests a positive trend for domestic pharmaceutical innovation [12][13] - The anticipated role of commercial insurance in supporting innovative drugs is expected to enhance market dynamics and pricing strategies, further benefiting the pharmaceutical sector [13][14]

3月5日，北证50成份指数涨超2.82%，同力股份、锦波生物、万通液压等多只北交所个股股价走出历史新 高。 记者注意到，近期大涨的多只北交所热门个股受到基金经理青睐，基金持仓比例相较去年同期均有所增加，随 着这些个股股价持续上涨，多只北交所主题基金年内业绩超过30%。 多位基金经理认为，北交所AI人工智能、低空经济、智能驾驶、机器人等领域均有质地不错的公司，这些符 合专精特新特点的细分行业龙头公司值得关注。 北交所个股人气高涨，基金加速买入 券商中国记者梳理发现，有多只公募基金重仓在这些创新高的热门股中，基金经理基于对北交所细分龙头企业 的看好持续加仓其中，这些龙头股的基金持仓比例逐步攀升。以同力股份为例，去年二季度、三季度基金持仓 比例分别是7.60%、6.58%，但四季度基金持仓比例达到8.29%。万通液压的基金持有比例从去年三季度的 4.85%提升至7.18%。 北交所主题基金业绩不俗 券商中国记者注意到，锦波生物、同力股份、曙光数创等近期大涨的北交所公司都是基金经理青睐的热门股， 在最新的机构持仓报告中，35只基金持有锦波生物、27只基金持有同力股份，22只基金持有曙光数创，基金持 仓比例相较去年同期 ...

Core Viewpoint - The article emphasizes the importance of systematic research and investment strategies in capturing value during industrial transformations, particularly in the context of China's technological advancements and the rise of AI applications [2][4][8]. Group 1: Investment Strategy - The investment strategy of the company focuses on identifying strong alpha opportunities amidst industrial changes, leveraging a long-term perspective to navigate the complexities of technological evolution [2][3]. - The company has established a systematic research framework that combines active and passive investment approaches across various markets and sectors, ensuring a robust investment strategy [8]. Group 2: Market Trends and Performance - In 2025, the A-share market experienced a significant technology rally, with the CSI TMT Index rising over 25%, driven by sectors such as domestic computing power and AI applications [6]. - Several funds managed by the company achieved impressive returns, with the Jia Shi Chuang Ye fund yielding 75.27% and the Jia Shi Chuang Xin fund yielding 69.16% over the past six months [6]. Group 3: Research and Development - The company's research team is characterized by a deep understanding of their respective fields, emphasizing the importance of developing a comprehensive framework and logical thinking to identify valuable companies [7]. - The research methodology is designed to be replicable and sustainable, focusing on continuous improvement and collaboration within the team to adapt to market changes [8].